Semaglutide and tirzepatide could avert cardiometabolic disease in thousands of obese people. But their high costs renders them economically unviable under current pricing. Tirzepatide’s price would need to drop by 30.5%, while semaglutide would require an 81.9% reduction to be cost effective.